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SUMMARY
Acebutolol (Sectral), a new beta-adrenoceptor antagonist,
was used in 4~ patients with cardiac arrhythmias (53
episodes). It was used intravenously (12,5 and 25 mg),
orally (100 mg every 8 hours) or in combination with quini-
dine. Acebutolol was most effective in supraventricular
tachyarrhythmias, to control the ventricular response when
digital's was ineF,ectiv~, as a synergist with quinidine to
convert patients to sinus rhythm, or prophylactically to
prevent relapse to atrial fibrillation. It also terminated
ventricular tachycardia in two patients.
Side-effects occurred in three ill patients.
S. Afr. Med. l., 48, 821 (1974).
Beta-adrenergic blocking agents are used in the manage-
ment of cardiac arrhythmias.'·7 Acebutolol (M&B 17803A;
Sectral; DL - 1 - (2 acetyl - 4 - butyramidophenoxy) - 2 -
hydroxy - 3 - isopropylaminopropane hydrocWoride) is a
new cardio,elective beta-adrenoceptor antagonist with great
affinity for, but low efficacy in, the beta receptor sites.
It also has membrane stabilising properties which may
make it a useful anti-arrhythmic agent.s In normal subjects,
the cardiac output at rest and on exercise is not altered by
the administration of acebutolol, and in patients with
coronary artery disease, intravenous acebutolol produces
a small fall in cardiac index, stroke index and in the
parameters which are used to measure left ventricular
contractilityYo
We have used acebutolol in 44 patients (53 episodes)
with cardiac arrhythmias to assess its value in therapy.
This is the initial report of the anti-arrhythmic use of the
drug in man.
PATIENTS AND METHODS
Acebutolol was used in 44 patients. The clinical data
relating to each patient, the nature of the arrhythmia,
route of administration of acebutolol and clinical out-
come, are shown in Table I, and summarised in Table n.
The patients were hospitalised for acute rhythm distur-
bances or followed carefully in an outpatient clinic for
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long-term management. The drug was administered intra-
venously to 14 patients while heart rate, the electrocardio-
gram, blood pressure and clinical status were monitored.
It was given orally to 39 patients.
The drug was given in 4 different dosage regimens:
Intravenous administration in a dose of 12,5 or 25 mg
to terminate an arrhythmia.
Oral administration in a dose of 100 - 200 mg every 8
or 12 hours to control a tachycardia, to abolish an arrhyth-
mia or to maintain sinus rhythm.
Combination therapy with quinidine after failure of
attempted conversion of a supraventricular arrhythmia
to sinus rhythm with quinidine or electroconversion, so
that each patient served as his own control. In these
patients quinidine was given in a dose of 400 mg every
6 hours for 4 doses; if sinus rhythm did not appear
electroconversion was attempted. If this failed or the patient
relapsed to atrial fibrillation on a prophylactic dose of
quinidine (200 mg every 8 hour), pharmacological con-
version to sinus rhythm was again attempted using
quinidine (400 mg every 6 hours) with the addition of
oral acebutolol (lOO mg every 8 hours). If this regimen
did not restore sinus rhythm after 24 hours, DC counter-
shock was given again.
Synergistic therapy of quinidine and acebutolol to main-
tain sinus rhythm in r-atients with atrial fibrillation or
flutter, in whom additional acebutolol was needed to
achieve cardioversion (quinidine 200 mg every 8 hours +
acebutolol 100 mg every 8 hours).
RESULTS
The results are summarised in Table n.
Ventricular Arrhythmias
Ventricular premature systoles (VPS). The drug was
given intravenously to 3 patients; it reduced the number
of VPSs in 1 patient with digitalis excess, and was
-ineffective in the other 2. It was given orally in another
3 patients; it reduced the number of VPSs per minute in
one, was effective for a short period in another, and was
ineffective in the third.
Ventricular tachycardia (VT). Acebutolol was given
intravenously to 3 patients; it terminated the tachycardia
in 2 and failed in a third, who became more hypotensive
after administration of the drug. Prophylactic oral admini-
stration of 200 mg acebutolol t.d.s. reduced the number
of paroxysms of VT in 1 of these patients; she can
terminate an episode of arrhythmia at home with a small
additional dose of the drug.
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TABLE I. THE PATIENTS
Result
Side-Age Dose of acebutolol Route of
Patients (yrs) Diagnosis (mg) administration + -+- effects
Ventricular premature
..... systoles..
C 1 34 Post-MVR 12,5 IV
III 2 18 AI; Dig. excess 12,5 IV +~
Co 3 59 CAD 25 IV
e 4 58 DVR; myopathy 100 every 8h Oral -+-... 5 73 Pacemaker 100 every 8h Oral01
"3 6 41 CAD 100 every 8h Oral +u.t: Ventricular tachycardia
C 7 27 Idiopathic 25 f 200 every 8 h IV + oral +Gl T
> 8 17 Idiopathic 25 IV f..
9 53 Post-DVR 12,5 IV Hypotension
Atrial premature systoles
or atrial echoes
10 61 Pacemaker 25 IV +
11 35 MVD 100 every 8h Oral +
12* 26 WPW 100 every 8h Oral
WPW + PAT
13 37 CAD 100 (single dose) Oral + Hypotension
14* 26 Idiopathic 25 IV
Nodal tachycardia
15 12 Post-MVR 15 IV
16 40 CAD 12,5 IV +
Atrial flutter/fibrillation
(a) Control rate
17 40 Post-MVR 12,5 IV + Hypotension
18 45 MS 25 IV +
19 40 MVD 25 IV +
20 9 Post-MVR 50 every 8h Oral +
21 25 Post-MVR 100 every 6h Oral +
22 39 MVD 100 every 8h Oral +
23 48 MVD 100 every 12 h Oral +
24 42 Postmitral valvulotomy 100 every 12 h Oral +....... (b) Cardioversion-..
c
.! without DC counter-
" shockCo! 25 9 Post-MVR 50 every 8h Oral +26 29 Postmitral valvulotomy 100 every 12 h Oral... 27 25 Postmitral valvulotomy 100 every 8h Oral +Cl!
"3 28 51 Post-MVR 100 every 8h Oral +u
;: 29 58 Idiopathic 100 every 8h Oral +C
Gl 30 63 Hypertension 100 every 8h Oral +>
Cl! 31 38 Post-MVR 100 every 8h Oral +...
Co 32 63 Pacemaker 12,5 IV +='Cl)
Cardioversion with
DC countershock
33 42 Post-DVR 100 every 8h Oral
34 34 Postmitral valvulotomy 100 every 8h Oral
35 25 Post-MVR 100 every 8h Oral
36 52 Post-DVR 100 every 8h Oral +
37 19 Post-MVR 100 every 8h Oral +
38 39 Post-pulmonary-valvulotomy 100 every 8h Oral +
39 31 Post-MVR 100 every 8h Oral +
(c) Long-term mainten-
ance of sinus rhythm
40 44 MS 100 every 12 h Oral +
41 51 MS 100 every 8h Oral +
42 41 MVD 100 every 8h Oral +
43 47 CAD 100 every 8h Oral +




52 63 CAD 100 every 8 h Oral +
53 86 Sick sinus syndrome 100 every 8 h Oral +
AI = aortic incompetence; CAD = coronary artery disease; DVR = double valve (aortic + mitral) replacement; MS mitral stenosis;
MVD = mixed mitral valve disease; MVR = mitral valve replacement; IV = intravenous; • = patients fall into 2 groups; WPW = Wolff-
Parkinson-White syndrome; PAT = paroxysmal atrial tachycardia.
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Arrhythmia patients IV Oral +
Ventricular 9
VPS 6 3 1
Ventricular tachycardia 3 1...
3 3 (1 ) 2
Supraventricular 44
APS 3 1 2 2
WPW + PAT 2 1 1 1
Nodal tachycardia 2 2 1
Atrial flutter/fibrillation
(a) Control rate 8 3 5 8
(b) Cardioversion 15 15
- without DC countershock 8
- with DC countershock 4
(c) Long-term maintenance of sinus rhythm 12 12 8
Tachycardia-bradycardia syndrome (+ pacing) 2 2 2
Total













Addition of acebutolol (100 mg every 8 h)
Quinidine and/or electroversion
No. Sinus rhythm on Sinus rhythm after Failure
No. of patients No. Success then relapse Failure drugs alone electroversion
15 13 5 8 13 6 4 3
2 2
2 patients were treated with acebutolol alone.
Supraventricular Arrhythmias
Atrial premature systoles (APS). The drug reduced the
number of APSs in 2 patients and was ineffective in one.
Wolff-Parkinson-White syndrome and paroxysmal atrial
tachycardia (PAT). The drug reduced the number of
episodes in one patient although it induced a period of
hypotension. It was ineffective in the second patient.
odal tachycardia. Acebutolol was given intravenously
to 2 patients with nodal tachycardia; it abolished the
arrhythmia in I and was ineffective in the other.
Atrial flutter or fibrillation. The drug was always effec-
tive in controlling the ventricular response in digitalised·
subjects when digitalis alone was inadequate.
Acebutolol was used for cardioversion in 15 patients
(Table Ill). Each patient was used as his own control,
and in 13 patients quinidine alone followed by electro-
conversion had been unsuccessful or the patient had
immediately relapsed into atrial fibrillation after success-
ful cardioversion. In 8 of the 15 patients sinus rhythm was
restored within 24 hours on a combination of quinidine
400 mg every 6 hours and acebutolol 100 mg every 8
hours. In the other 7 patients electroconversion was
applied after 24 hours and was successful in 4.
11
Eight patients of this group were maintained on qUlOl-
dine and acebutolol to prevent recurrence of atrial fibrilla-
tion over a period of 3 months or longer; 4 relapsed into
atrial fibrillation and 4 remained in sinus rhythm. Another
group of 4 patients with intermittent atrial fibrillation were
treated with oral acebutolol alone in a dose of 100 mg
every 8 or 12 hours; atrial fibrillation did not recur in
one patient and the number of episodes was reduced in
the other 3.
Tachycardia-bradycardia syndrome. Both patient in this
group had intermittent complete heart block and parox-
ysms of atrial flutter with rapid ventricular response.
A demand pacemaker was inserted to control the brady-
cardia, and acebutolol prevented further episodes of supra-
ventricular tachycardia.
Side-Effects
Ventricular tachycardia with hypotension after aor-
tic and mitral valve replacement. Aortic and mitral valve
replacement was undertaken in a 53-year-old woman.
Ventricular tachycardia developed 12 hours after operation.
The patient was hypotensive and hypovolaemic. lntraven-
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ous acebutolol (12,5 mg) did not abolish the tachycardia
and the patient's hypotension increased. This was corrected
by administration of isoprenaline and intravenous fluids.
Rapid ventricular response to atrial fibrillation after
mitral valve replacement (MVR). A 40-year-old woman
developed rapid atrial fibrillation 24 hours after MVR.
Acebutolo! 12,5 mg intravenouslv reduced the ventricular
rate from 150 to lID beats/min: but the patient became
cold and sweaty and the sysrolic pressure feU to less than
50 mmHg. The patient responded to intravenous isopre-
naline, the systolic blood pressure increased to 100 - liD
mmHg and the ventricular rate to 130 beats/min.
Recurrent atrial tachycardia in the Wolff-Parkinson-
White syndrome (WPW) and coronary artery disease.
A 37-year-old man who had had two episodes of acute
myocardial infarction was shown at cardiac catheterisation
and cine-angiocardiography to have triple vessel coronary
artery disease and extensive ventricular asynergy. His
left ventricular end-diastolic pressure was 26 mmHg and
the ejection fraction 31 %. He also had the WPW syndrome
and 10-30 episodes of paroxysmal atrial tachycardia
(PAT) per day. Each episode of tachycardia was associated
with hypotension and precipitated pulmonary oedema. A
single oral dose of 100 mg acebutolol was given: this
abolished the episodes of tachycardia but the patient
became hypotensive within 3 hours and required isopre-
naline assistance for the following 12 hours.
Chronic side-effects were not observed.
DISCUSSION
Beta-adrenoceptor antagonists appear to have a specific
mode of action in the management of arrhythmias."
They may act by antagonising the action of catechol-
amines, by a local anaesthetic action, or by a quinidine-like
effect in which phase 0 of the action potential may be
altered. Acebutolol has all these effects, but extensive
studies with other drugs suggest that in the dosage used
in clinical practice, the beta-adrenoceptor effects are more
important than the other two.' There are numerous reports
of the efficacy of propranolol, practolol, sotalol and alpren-
0101: these drugs have been used to suppress atrial and
ventricular premature systoles and to terminate supra-
ventricular tachyarrhythmias.s",I,,13 The combination ther-
apy of quinidine and beta blockade is effective in converting
atrial fibrillation to sinus rhythm."'"
In our study, acebutolol was most effective in supra-
ventricular arrhythmias: it was a good drug to control a
rapid ventricular response when digitalis alone was ineffec-
tive, it was a powerful synergist with quinidine in convert-
ing patients to sinus rhythm (with or without DC counter-
shock) and was useful as an adjunct to quinidine in the
maintenance of sinus rhythm after this had been restored.
It compares favourably with other beta-blocking agents
used in similar circumstances, but we do not know how
to compare individual drugs with each other. Acebutolol
was also capable of terminating ventricular tachycardia
and of preventing recurrences of this arrhythmia. Its value
in the suppression of different kinds of ventricular pre-
mature systoles needs further study. We did not have the
opportunity to use acebutolol in the circumstance of acute
myocardial infarction.
Serious side-effects were encountered in only 3 patients,
In 2 patients intravenous acebutolol was administered
within 24 hours of cardiopulmonary bypass, while the
third patient had severe left ventricular dysfunction; he
was critically dependent on sympathetic drive for mainte-
nance of an adequate cardiac output, and administration
of a single dose of the beta-blocking drug produced pro-
found hypotension and cardiac failure. Prolonged oral
administration was not associated with untoward effects.
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